Bioventus Inc. (BVS)Healthcare | Medical Devices | Durham, United States | NasdaqGS
13.84 USD
+0.05
(0.363%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.84 |
Hot Take ↕ | Aug. 22, 2026, 4:32 a.m. EDT
Bioventus presents a classic value trap scenario where strong balance sheet metrics mask a deteriorating business reality. Despite a healthy Return on Equity of 25.7% and positive free cash flow, the stock has suffered a catastrophic 50% decline over the last four years, with the most recent annual performance showing another drop. This multi-year structural decline suggests the market has permanently repriced the company's growth prospects, rendering the current valuation attractive only if a turnaround occurs immediately. The short-term outlook remains murky. While the stock recently rallied off its lows, the technical setup is fragile, trading near its 50-day average but still well below its 200-day line. More concerning is the options flow, which screams caution; traders are buying insurance against further drops rather than anticipating a breakout. The statistical forecast model offers no help, predicting a negligible drift with low confidence, confirming that price action is currently noise. Fundamentally, the company is not generating a dividend, eliminating income as a buffer. The 'Strong Buy' analyst consensus appears disconnected from the harsh reality of the price trajectory, likely based on potential catalysts like the acquisition proposal mentioned in recent news, but these are speculative events, not guaranteed earnings drivers. Until the price history shows a sustained recovery or the acquisition materializes with concrete terms, the risk of further downside outweighs the potential for a quick rebound. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.246995 |
| AutoETS | 0.249723 |
| MSTL | 0.252062 |
| AutoTheta | 0.257094 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 45.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.192 |
| Excess Kurtosis | -1.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 95.075 |
| Revenue per Share | 8.647 |
| Market Cap | 945,343,232 |
| Trailing P/E | 17.74 |
| Forward P/E | 15.04 |
| Beta | 0.65 |
| Profit Margins | 9.36% |
| Website | https://www.bioventus.com |
As of Aug. 22, 2026, 4:32 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 7.5 and 10.0) relative to calls. Implied volatility is significantly elevated for puts compared to calls, indicating a fear premium. While some call volume exists at lower strikes, the overwhelming capital deployment is in hedging against further declines rather than betting on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9099723 |
| Address1 | 4,721 Emperor Boulevard |
| Address2 | Suite 100 |
| All Time High | 19.941 |
| All Time Low | 0.8 |
| Ask | 13.86 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 583,290 |
| Average Daily Volume3 Month | 741,930 |
| Average Volume | 741,930 |
| Average Volume10Days | 583,290 |
| Beta | 0.653 |
| Bid | 13.88 |
| Bid Size | 5 |
| Board Risk | 5 |
| Book Value | 3.347 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.84 |
| Current Ratio | 1.689 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 13.965 |
| Day Low | 13.725 |
| Debt To Equity | 95.075 |
| Display Name | Bioventus |
| Earnings Call Timestamp End | 1,785,933,000 |
| Earnings Call Timestamp Start | 1,785,933,000 |
| Earnings Growth | 3.273 |
| Earnings Quarterly Growth | 3.483 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 80,145,000 |
| Ebitda Margins | 0.13774 |
| Enterprise To Ebitda | 15.32 |
| Enterprise To Revenue | 2.11 |
| Enterprise Value | 1,227,804,160 |
| Eps Current Year | 0.778 |
| Eps Forward | 0.92 |
| Eps Trailing Twelve Months | 0.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.2904 |
| Fifty Day Average Change | 1.5496006 |
| Fifty Day Average Change Percent | 0.1260822 |
| Fifty Two Week Change Percent | 90.99723 |
| Fifty Two Week High | 15.893 |
| Fifty Two Week High Change | -2.0529995 |
| Fifty Two Week High Change Percent | -0.12917633 |
| Fifty Two Week Low | 6.255 |
| Fifty Two Week Low Change | 7.585 |
| Fifty Two Week Low Change Percent | 1.2126299 |
| Fifty Two Week Range | 6.255 - 15.893 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,613,053,800,000 |
| Float Shares | 34,297,378 |
| Forward Eps | 0.92 |
| Forward P E | 15.043478 |
| Free Cashflow | 67,764,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 950 |
| Fullday Change | 0.0500002 |
| Fullday Change Percent | 0.362583 |
| Fullday Price | 13.84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.68651 |
| Gross Profits | 399,446,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.116510004 |
| Held Percent Institutions | 0.82075 |
| Implied Shares Outstanding | 68,305,143 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-02-11 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. |
| Long Name | Bioventus Inc. |
| Market | us_market |
| Market Cap | 945,343,232 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_154172707 |
| Most Recent Quarter | 1,782,518,400 |
| Net Income To Common | 54,464,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,160,047,483 |
| Number Of Analyst Opinions | 5 |
| Open | 13.84 |
| Operating Cashflow | 96,873,000 |
| Operating Margins | 0.122279994 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.79 |
| Phone | 919 474 6700 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.84 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 13.79 |
| Price Eps Current Year | 17.789204 |
| Price Hint | 2 |
| Price To Book | 4.1350465 |
| Price To Sales Trailing12 Months | 1.6247255 |
| Profit Margins | 0.09361 |
| Quick Ratio | 1.107 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.0500002 |
| Regular Market Change Percent | 0.362583 |
| Regular Market Day High | 13.965 |
| Regular Market Day Low | 13.725 |
| Regular Market Day Range | 13.725 - 13.965 |
| Regular Market Open | 13.84 |
| Regular Market Previous Close | 13.79 |
| Regular Market Price | 13.84 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 445,693 |
| Return On Assets | 0.054899998 |
| Return On Equity | 0.25684 |
| Revenue Growth | 0.038 |
| Revenue Per Share | 8.647 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 68,305,143 |
| Shares Percent Shares Out | 0.0342 |
| Shares Short | 2,334,332 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,729,359 |
| Short Name | Bioventus Inc. |
| Short Percent Of Float | 0.0498 |
| Short Ratio | 2.94 |
| Source Interval | 15 |
| State | NC |
| Symbol | BVS |
| Target High Price | 19.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.6 |
| Target Median Price | 18.0 |
| Total Cash | 30,394,000 |
| Total Cash Per Share | 0.445 |
| Total Debt | 263,748,992 |
| Total Revenue | 581,848,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.78 |
| Trailing P E | 17.743591 |
| Trailing Peg Ratio | 1.7573 |
| Triggerable | 1 |
| Two Hundred Day Average | 9.508875 |
| Two Hundred Day Average Change | 4.3311253 |
| Two Hundred Day Average Change Percent | 0.45548242 |
| Type Disp | Equity |
| Volume | 445,693 |
| Website | https://www.bioventus.com |
| Zip | 27,703 |